Few Buyers + Few Analysts Covering Alexza/CC + Undefined Royalty % Shedule to Alexza from Teva =
Few Buyers + Few Analysts Covering Alexza/CC + Undefined Royalty % Shedule to Alexza from Teva = Disapointing Stock Movement Tomorrow. I hope I am wrong because I am long ALXA. What factors do you see that I don't that will drive this stock up in the next week?
new drug in production, no cap raise , ramping up for getting to market in US and EU. smaller payout to acquiring co / cap at 10%, reduced burn.... i thought it was a all positive . i think we start the climb to 8.
Cab - good points. A few other positives from the cc were that only $2.5M left to pay Symphony at the 25% level (to reach the $100M) before going to 10%, and that King mentioned the possibility of partnerships for China, India and Japan in the future. I thought it was curious that no analyst asked about the basis of royalty payments to Alexza. Seems one would want to know that to project revenues.